Resuscitative effect of a γ-aminobutyric acid B receptor antagonist on γ-hydroxybutyric acid mortality in mice

被引:20
作者
Carai, MAM
Colombo, G
Gessa, GL
机构
[1] Univ Cagliari, Bb Brodie Dept Neurosci, Sch Med, I-09126 Cagliari, Italy
[2] CNR, Inst Neurosci, Sect Cagliari, Cagliari, Italy
关键词
D O I
10.1016/j.annemergmed.2004.12.013
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Study objective: In the present study, a number of compounds were tested to evaluate their efficacy in exerting a protective effect on gamma-hydroxybutyric acid (GHB)-induced mortality in mice. The drugs investigated were the gamma-aminobutyric acid B (GABA(B)) receptor antagonist SCH 50911, the GABA(A) receptor antagonist bicuculline, the benzodiazepine receptor antagonist flumazenil, the putative GHB receptor antagonist NCS-382, the opioid receptor antagonist naltrexone, and the amino acid and possible neuromodulator, taurine. Methods: All mice were initially treated with a lethal dose of GHB (7 g/kg, administered intragastrically). Once mice had displayed clear signs of GHB intoxication, animals from each group were treated acutely with either SCH 50911 (vehicle; 75, 150, and 300 mg/kg, administered intraperitoneally), bicuculline (vehicle; 2, 4, 6, and 8 mg/kg, administered intraperitoneally), flumazenil (vehicle; 1, 3, and 10 mg/kg, administered intraperitoneally), NCS-382 (vehicle; 50 and 200 mg/kg, administered intraperitoneally), naltrexone (vehicle; 3 and 10 mg/kg, administered intraperitoneally), or taurine (vehicle; 250 and 750 mg/kg, administered intraperitoneally). The various doses of each single drug were administered to 10 mice, randomly allocated throughout the experimental groups. Mortality was recorded every hour for the first 9 hours and subsequently 12, 18, and 24 hours after GHB injection. Results: In each experiment, all vehicle-treated mice died within 24 hours of GHB injection. Doses of 150 and 300 mg/kg SCH 50911 produced a marked protection on GHB-induced mortality, evidenced by the death of only 0 of 10 and 2 of 10 mice in the 150- and 300-mg/kg SCH 50911 groups, respectively. In contrast, at all doses tested, bicuculline, flumazenil, NCS-382, naltrexone, and taurine were not observed to exert any protective effect on GHB-induced mortality (9 to 10/10 mice died in each treatment group). Conclusion: These results suggest an involvement of the GABAB receptor, at least in rodents, in the mediation of the lethal effects of GHB.
引用
收藏
页码:614 / 619
页数:6
相关论文
共 22 条
[1]   Cloning and characterization of a rat brain receptor that binds the endogenous neuromodulator γ-hydroxybutyrate [J].
Andriamampandry, C ;
Taleb, O ;
Viry, S ;
Muller, C ;
Humbert, JP ;
Gobaille, S ;
Aunis, D ;
Maitre, M .
FASEB JOURNAL, 2003, 17 (10) :1691-+
[2]   GABAB receptor-mediated increase of neurosteroids by γ-hydroxybutyric acid [J].
Barbaccia, ML ;
Colombo, G ;
Affricano, D ;
Carai, MAM ;
Vacca, G ;
Melis, S ;
Purdy, RH ;
Gessa, GL .
NEUROPHARMACOLOGY, 2002, 42 (06) :782-791
[3]  
Bernasconi R, 2002, GAMMA-HYDROXYBUTYRATE: MOLECULAR, FUNCTIONAL, AND CLINICAL ASPECTS, P28, DOI 10.4324/9780203300992_chapter_3
[4]   USING ANTAGONISTS TO ASSESS NEUROCHEMICAL CODING OF A DRUGS ABILITY TO ESTABLISH A CONDITIONED PLACE PREFERENCE [J].
BILSKY, EJ ;
MARGLIN, SH ;
REID, LD .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1990, 37 (03) :425-431
[5]   Role of GABAB receptors in the sedative/hypnotic effect of γ-hydroxybutyric acid [J].
Carai, MAM ;
Colombo, G ;
Brunetti, G ;
Melis, S ;
Serra, S ;
Vacca, G ;
Mastinu, S ;
Pistuddi, AM ;
Solinas, C ;
Cignarella, G ;
Minardi, G ;
Gessa, GL .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 428 (03) :315-321
[6]   Effects of the putative antagonist NCS382 on the behavioral pharmacological actions of gammahydroxybutyrate in mice [J].
Cook, CD ;
Aceto, MD ;
Coop, A ;
Beardsley, PM .
PSYCHOPHARMACOLOGY, 2002, 160 (01) :99-106
[7]  
Feigenbaum JJ, 1997, NEUROSCI LETT, V224, P71
[8]  
Gobaille S, 1999, J PHARMACOL EXP THER, V290, P303
[9]   Therapeutic intervention in mice deficient for succinate semialdehyde dehydrogenase (γ-hydroxybutyric aciduria) [J].
Gupta, M ;
Greven, R ;
Jansen, EEW ;
Jakobs, C ;
Hogema, BM ;
Froestl, W ;
Snead, OC ;
Bartels, H ;
Grompe, M ;
Gibson, KM .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 302 (01) :180-187
[10]  
Hechler V, 1997, J PHARMACOL EXP THER, V281, P753